RETINAFLUX THERAPEUTICS
Live / Applied — New application — not yet assigned to an examiner (as of 09 Sept 2026)
What this means for you
Not registered yet, but its 09 Sept 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 50098134
- Mark type
- Stylized text
- Filed
- 09 Sept 2026
- Attorney of record
- Nasser Khateeb
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of ophthalmic diseases; pharmaceutical preparations for the treatment of glaucoma; neuroprotective pharmaceutical preparations; drug delivery formulations for ocular use; therapeutic agents for preventing or slowing neurodegeneration; pharmaceutical preparations for the treatment of retinal and optic nerve disorders; biologics and small molecule therapeutics for neurological and ophthalmic indications.
- Class 042 — Scientific and technological services: Biotechnology research and development services; pharmaceutical research and development; research and development of neuroprotective therapeutics; laboratory research services in the field of ophthalmology, glaucoma, and neurodegeneration; drug discovery services; preclinical research services; development of drug delivery systems; scientific research for medical purposes in the field of ocular and neurological diseases.
- Class 044 — Medical, beauty and agricultural services: Medical and clinical services relating to the diagnosis, prevention, and treatment of ophthalmic and neurodegenerative diseases; conducting clinical trials for pharmaceutical preparations; medical information services in the fields of ophthalmology, glaucoma, and neuroprotection.
Owner
- Retinaflux Therapeutics Corp., Washington, DC, US
Prosecution history
- 09 Sept 2026 — APPLICATION FILING RECEIPT MAILED
- 09 Sept 2026 — NEW APPLICATION ENTERED